Ultragenyx Takes Second Hit as FDA Rejects Gene Therapy for Sanfilippo Syndrome

The FDA cited manufacturing issues but did not flag problems with Ultragenyx’s data package for UX111, with the biotech noting that the regulator found its neurodevelopmental findings for the gene therapy to be “robust.”